Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan ADME study in healthy males
NCT02962440Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of somapacitan in growth hormone deficiency (GHD), sponsored by Novo Nordisk. Primary endpoints: Total amount of [3H]-somapacitan related material excreted in urine at 35 days, Total amount of [3H]-somapacitan related material excreted in faeces at 35 days and 1 more. Started Nov 2016; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02962440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962440.